Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 2018; 36: 2796-2803.
Published: 22nd March 2019
Authors: Yang H, Liu Y, Chen Y, Zhu C, Fang W, Yu Z et al.
Use of neoadjuvant therapy in this study of 451 procedures increased the R0 resection rate (98.4 versus 92.1 per cent, P=0.002), and improved median overall survival from 66.5 to 100.1 months: hazard ratio 0.71, 95 per cent confidence interval 0.53 to 0.96, P=0.025.Pubmed Link
You may also be interested in
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957.
Authors: Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al.
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). EJSO 2017; 43: 1550-1558.
Authors: Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Nowak K, Kieser M et al.
Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg 2017; 265: 481-491.
Authors: Pasquali S, Yim G, Vohra R , Mocellin S, Nyanhongo D, Marriott P et al.
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol 2017; 18: 357-370.
Authors: Cunningham D, Stenning SP , Smyth EC, Okines AF, Allum WH, Rowley S et al.
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422.
Authors: Mariette C, Dahan L, Mornex F, Maillard E, Thomas P-A, Meunier B et al. et al.
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387–4393.
Authors: Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. et al.
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466–472.
Authors: Zhang X-L, Shi H-J, Cui S-Z, Tang Y-Q, Ba M-C.
Effect of early oral feeding after gastric cancer surgery: a result of randomised clinical trial. Surgery 2011; 149: 561–568.
Authors: Hur H, Kim SG, Shim JH, Song KY, Kim W, Park CH et al. et al.
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III Trial. J Clin Oncol 2011; 29: 1715–1721.
Authors: Ychou M, Boige V, Pignon J-P, Conroy T, Bouche O, Lebreton G et al. et al.
Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg 2011; 253: 1-5.
Authors: Teoh AYB, Yan C, Philip W, Wong TCL, Liu SYW, Hung W et al. et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–697.
Authors: Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al.